Introduction
Members of the myb gene family (A-myb, B-myb and c-myb) play an essential role during development (Oh and Reddy, 1999) . The c-Myb proto-oncogene, cellular homolog of the avian myeloblastosis virus (AMV) and avian leukemia virus (E26) transforming genes (Klempnauer et al., 1984) , is predominantly expressed in hematopoietic tissues and plays a role in tumorigenesis (Ness, 1999; Weston, 1999; Davies et al., 1999) . c-Myb is a transcription factor that transactivates several cellular promoters (reviewed in Thompson and Ramsay, 1995) . This protein possesses three distinct functional domains: a DNA binding domain (DBD), a transactivating domain (TA), and a negative regulatory domain (NRD) (Sakura et al., 1989) . CBP, C/EBPb, C/EBPe, pim1 and p100 have been shown to increase c-Myb-dependent transcription (Dai et al., 1996; Oelgeschlager et al., 1996; Mink et al., 1996; Verbeek et al., 1999; Ness, 1999) while interaction between c-Myb and other proteins such as p67, ATBF1, Cyp-40, c-Maf and c-Myb inhibits c-Myb-dependent transcription (Tavner et al., 1998; Dash et al., 1996; Kaspar et al., 1999; Hedge et al., 1998; Nomura et al., 1993; Ness, 1999) .
Regulation of c-Myb expression is complex and occurs at the transcriptional, post-transcriptional and post-translational levels. The c-Myb promoter can be activated through Ets-like and CMAT sites (Sullivan et al., 1997; Phan et al., 1996) or by c-Jun, JunD (Nicolaides et al., 1992) . The Wilms' tumor suppressor WT-1, B-Myb and c-Myb proteins have been identi®ed as repressors of the c-Myb promoter activity (McCann et al., 1995; Foos et al., 1992; Nomura et al., 1993) . A blockade to transcription elongation has been identi®ed within the ®rst intron of the mouse c-Myb locus (Bender et al., 1987; Watson, 1988) , and a correlation between proteins binding to the intron 1 pause site and c-Myb mRNA levels has been reported (Reddy and Reddy, 1989; Castron et al., 1992) .
HTLV-I is the etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL). Although HTLV-I infects predominantly CD4 + T-cell in vitro and in vivo, the establishment of CD8 + T-cell lines from infected donors has also been reported (Nicot et al., 1993) . The viral transactivator Tax has been shown to target key regulators of the cell cycle such as p16 ink4A , p21 waf1/cip1 , p53 and MAD-1 (Suzuki et al., 1996; Cereseto et al., 1996; Akagi et al., 1997; Pise-Masison et al., 1998; Mulloy et al., 1998; Jin et al., 1998) . The pleiotropic eects of Tax result from its ability to activate transcription through distinct pathways, including CREB/ATF, NF-kB and SRE, and to alter the expression of numerous cellular genes. Tax can engage itself in a multi-protein complex, including CREB and CBP/p300, essential for Tax stimulation of transcription from the viral LTR (Giebler et al., 1997; Harrod et al., 1998) . In addition, Tax has been shown to repress cellular promoters containing E-box motifs such as the b-polymerase and Lck (Jeang et al., 1990; Lemasson et al., 1997) .
A previous report proposed that Tax inactivates transactivation potential of the c-Myb protein by competing directly for the recruitment of CBP (Colgin and Nyborg, 1998) . We tested whether such a competition could aect transcription from the c-Myb promoter. In this study we demonstrate that Tax suppression of c-Myb transactivation results in transrepression of the c-Myb promoter through the Myb responsive elements in Jurkat T-cells. However, the ability of Tax and Tax mutants to repress the c-Myb promoter was independent from their relative abilities to bind to CBP or p300 in vitro. Interestingly, a decreased transcription from the endogenous c-Myb promoter was observed in several HTLV-I transformed T-cell lines. A direct eect of Tax on the endogenous cMyb promoter was demonstrated in Jurkat T-cells stably transfected with a Tax inducible vector. Consequent to transcription down-regulation, low levels of c-Myb protein were also found in HTLV-I transformed cells.
Results

Repression of the c-Myb promoter by the tax protein through the Myb responsive elements (MRE) in Jurkat T-cells
HTLV-I Tax is known to aect the transcriptional regulation of numerous cellular promoters. A previous report suggested that Tax suppresses c-Myb-dependent transcription in a model whereby Tax and c-Myb enter in direct competition, in a mutually exclusive manner, for the recruitment of CBP (Colgin and Nyborg, 1998) . We tested whether such a competition could aect transcription from the human c-Myb promoter in Tax expressing cells. In transient transfection assays in Jurkat T-cells, Tax was able to repress the basal level of transcription from a c-Myb promoter luciferase construct. In order to delineate which elements within the c-Myb promoter were required for Tax's eect, several c-Myb promoter luciferase constructs carrying mutations in dierent responsive elements were used (Figure 1a ). Previous studies using gel shift assay and UV cross-link analyses have shown the binding of the c-Myb and the Wilm's tumor suppressor proteins to the MRE and WT1 sites respectively (Nicolaides et al., 1991; Guerra et al., 1995; McCann et al., 1995) . Mutations were introduced in these sites (constructs in Figure 1a ) and shown to abrogate the DNA binding activity of cMyb or WT1 proteins McCann et al., 1995) . McCann et al., 1995) . The presence of a hatched box indicates location for Myb responsive sites (MRE) I and II and the Wilm's tumor suppressor (WT1) binding site. The box was omitted when a mutation that abrogated DNA binding of c-Myb or WT1 was introduced in that element. The basal level of transcription of each construct was compared to levels of transcription in the activated state as induced by transfection of a c-Myb expression plasmid. Consistent with previous ®ndings in Molt4 Tcells, the basal activity of the c-Myb promoter increased when both MRE I and II sites were mutated (Myb5), suggesting that these sites may act as negative regulators of the c-Myb promoter basal activity ( Figure  1b) . However, in the activated state, c-Myb transactivated its own promoter when at least one of the MRE sites was present (Figure 1c) . Thus, the MRE sites appear to be involved in both negative and positive regulation of the c-Myb promoter depending on the levels of c-Myb expression.
In transient transfection assays in Jurkat T-cells, Tax expression resulted in more than 60% reduction in the basal level of transcription when one Myb responsive element (MRE I or MRE II, Myb3 and Myb4 constructs), or when the Wilm's tumor suppressor binding site (WT1, Myb6 construct) was mutated ( Figure 2 ). This eect was abrogated when both MRE I and II were mutated simultaneously ( Figure  2 , Myb5 construct). Since this construct had high levels of basal activity (Figure 1b) , these results indicated that the presence of at least one MRE site was required and sucient for Tax-mediated transrepression of the human c-Myb promoter.
Tax mutant defective in transrepression of the c-Myb promoter still interacts with CBP and p300
Like many transcription factors, Tax and c-Myb transactivation potential rely on the recruitment of coactivators CBP/p300 to the promoter region. Previous studies have shown that c-Myb and Tax proteins interact with the same region of CBP in a signal-independent manner, amino acid residues 461 ± 661 and 451 ± 682, respectively (Dai et al., 1996; Oelgeschlager et al., 1996; Kwok et al., 1996) . Because c-Myb can transactivate its own promoter in Jurkat T-cells (Figure 1c) , we tested whether competition between c-Myb and Tax for the recruitment of CBP or p300 could explain Tax-mediated repression of the c-Myb promoter. To this end, we used wild type (WT) Tax and several Tax mutants, M22, M47 and V89A, that have been previously characterized (Smith and Greene, 1990; Harrod et al., 1998) . In the case of WT Tax and V89A, binding to CBP in vitro has been previously described, using GST-CBP, aa 451 ± 682 (Harrod et al., 1998) . However, because this small fragment of CBP may not be representative of the complete protein (2441 aa), we investigated the direct binding of Tax and Tax mutants to the full-length CBP protein. In vitro translated radiolabeled protein WT Tax, and the Tax mutants M22 and M47, were incubated with full-length in vitro translated radiolabeled CBP protein. Comparable amounts of Tax and Tax mutant proteins were used in each binding reaction, as shown by immunoprecipitation using a Tax monoclonal antibody (Figure 3a ). Antibodies directed against CBP co-precipitated to the same extent as the WT Tax protein and the mutants M22 (Figure 3a ), indicating no signi®cant dierence in the binding of these proteins to the full-length CBP protein. Consistent with a previous report, M47 showed a decreased binding of the full-length CBP (Bex et al., 1998) . Speci®city of the antibody to CBP was con®rmed by the absence of Tax protein in the immunoprecipitate when CBP was mixed with the luciferase protein (Figure 3a , Luciferase) or when Tax protein was incubated in the absence of CBP ( Figure  3a , control).
In the case of p300, the direct binding of WT Tax and Tax mutants M22 and M47 has not been previously tested. Using the same experimental approach we also demonstrated that Tax and Tax mutant proteins directly bind to the full-length p300 protein with no signi®cant dierence ( Figure 3b ). Speci®city of the antibody to p300 was con®rmed by the absence of Tax in the immunoprecipitate when p300 was incubated with luciferase protein (Figure 3b , Luciferase) or when Tax protein was incubated in the absence of p300 (Figure 3b, control) .
Interaction of Tax with CBP/p300 is essential for transactivation of the viral LTR (Giebler et al., 1997; Harrod et al., 1998) . As expected from the in vitro binding results, both WT Tax and M22 transactivate the HTLV-I LTR to a similar extent in Jurkat T-cells ( Figure 3c ). As recently shown, the absence of HTLV-I LTR transactivation by M47 presumably results from its impaired binding to the p300 acetyltransferase factor PCAF (Jiang et al., 1999) . The relative ability of each Tax mutant to repress the cMyb promoter luciferase was then compared in transient transfection assays in Jurkat T-cells. While both WT and M47 were able to signi®cantly repress transcription from the c-Myb promoter, M22 was not ( Figure 3d ). Because M22 and WT Tax bind CBP/ p300 to a similar extent and the binding of M22 to CBP/p300 is similar to or greater than M47, it appears that Tax repression of the c-Myb promoter is independent of a direct competition between Tax and c-Myb for the recruitment of CBP/p300. These results were not dependent on dierences in protein stability in vivo since Western blot analysis revealed comparable expression of these constructs in transient transfection assay (Figure 3e ). To further demonstrate that Tax interaction with CBP and p300 was dispensable for the repression of the cMyb promoter activity, we used a Tax mutant defective for CBP interaction (Harrod et al., 1998) . Tax V89A carries a single point mutation within the CBP/p300 binding domain and this protein does not interact with GST-CBP (Harrod et al., 1998) . In fact, in our experimental conditions, interaction of Tax V89A with full-length protein CBP was greatly reduced when compared to M22 (Figure 4a ). In addition, interaction of V89A with p300 was also markedly attenuated ( Figure 4b ). Consistent with these results, V89A was also defective for CBP and p300 binding in vivo (Nicot and Harrod, submitted) . As expected from these observations, Tax V89A transactivation of the HTLV-I LTR was inecient in Jurkat T-cells ( Figure  4c ). However, in spite of its impairment in binding to CBP and p300, Tax V89A represses transcription from the c-Myb promoter more eciently than M22 ( Figure  4d ). Similar expression of M22 and V89A in transient transfection assay was con®rmed by Western blot S-methionine labeled Tax and CBP proteins were incubated in binding buer, immunoprecipitated with a CBP antibody, and resolved onto 4 ± 20% SDS ± PAGE followed by¯uorography and autoradiography as described under Materials and methods. Comparable amounts of Tax WT, M47, and M22 proteins used in each binding reaction were con®rmed by immunoprecipitation using a Tax monoclonal antibody. Results are representative of two separate experiments. Speci®city of the antibody to CBP was con®rmed by the absence of Tax in the immunoprecipitate when CBP was incubated with Luciferase protein (Luciferase) or when Tax protein was incubated in the absence of CBP (control). (b) In vitro binding of Tax and Tax mutants M22 and M47 to the full-length p300. Binding to p300 was carried out as described under Materials and methods. Comparable amounts of Tax WT, M47, and M22 proteins used in each binding reaction were con®rmed by immunoprecipitation using a Tax monoclonal antibody. Results are representative of two independent experiments. Speci®city of the antibody to p300 was con®rmed by the absence of Tax in the immunoprecipitate when p300 was incubated with Luciferase protein (Luciferase) or when Tax protein was incubated in the absence of p300 (control). proteins such as IkBa and IkBb to the ubiquitinproteasome degradation pathway (Brockman et al., 1995; McKinsey et al., 1996) . However, c-Myb expression was not signi®cantly aected when CMVc-Myb and CMV Tax were co-expressed in transient transfection assays (Figure 5b ), suggesting that Tax suppression of c-Myb transactivation potential and the consequent repression of the c-Myb promoter are not direct consequences of a decrease in c-Myb at the protein level. All together, our results indicate that Tax repression of the c-Myb promoter results from inactivation of c-Myb transactivating functions and that this eect is independent of CBP/p300 binding.
Transcriptional repression of the endogenous c-Myb promoter by Tax in HTLV-I-transformed cells and Tax inducible Jurkat cell line
Observations made in transient transfection assays using promoter reporter constructs may not always be representative of the situation found with an endogenous promoter. To validate the eect of Tax on the endogenous c-Myb promoter, we investigated the levels of c-Myb mRNA in several HTLV-I transformed T cell lines. Total RNA was extracted from exponentially growing cells and analysed by Northern blot using either a c-Myb cDNA probe or the GADPH as a probe control for RNA loading (Figure 5a ). In HTLV-I cell lines that express Tax, the levels of c-Myb mRNA were lower than in Jurkat T cells. Since in two of these cell lines, C8166 and MT4, Tax is the only viral protein detectable, this ®nding correlates with the observation that transient transfection of Tax in Jurkat T-cells represses the c-Myb promoter luciferase construct. However, because these cell lines have been established after long-term culture in vitro, it remained possible that other genetic defects, rather than Tax expression, may be responsible for the transrepression of the c-Myb promoter. To assess the ability of Tax to directly repress the endogenous c-Myb promoter, we used a Jurkat cell line stably transfected with a tax gene driven by a cadmium-inducible promoter (JPX9) (Tatewaki et al., 1995) . Consistent with previous reports, induction of Tax expression in these cells was transient and maximum expression was achieved between 6 ± 8 h following induction and decreased thereafter (Figure 5b ). Importantly, transcription of c-Myb mRNA in JPX9 cells decreased when maximum Tax expression was achieved and recovered their original levels after that Tax expression had disappeared (Figure 5b ). GADPH was used as a probe control for RNA loading. This eect on the endogenous c-Myb promoter was speci®cally due to the induction of Tax expression as no eect was observed on the Jurkat cell line control treated in the same conditions (Figure 5b , lanes 1 ± 3). These results indicate that Tax directly transrepresses the human cMyb promoter in T-cells. In agreement with these results, Western blot analysis indicated a low level of cMyb protein expression in HTLV-I transformed cells (Figure 5c ). In addition to Jurkat T-cells, other leukemic T-cell lines such as CEM and Molt-4 also express high levels of c-Myb protein (data not shown). Interestingly, higher levels of c-Myb protein were found in some HTLV-I infected cell lines (C10MJ, 1185, and 1186), in which Tax protein expression was barely detectable.
Discussion
c-Myb promoter transrepression by Tax is independent of its interaction with CBP or p300
To date, Tax has been demonstrated to down-regulate the cellular promoters of the b-polymerase and Lck genes (Jeang et al., 1990; Lemasson et al., 1997) . The results presented here indicate that Tax also represses transcription from the endogenous human c-Myb promoter in vivo. In contrast with its transactivating function, which has been intensively studied, transrepression by Tax Colgin and Nyborg described an in vitro competition between Tax and c-Myb proteins for binding to CBP and proposed that this competition resulted in Tax repression of c-Myb transactivation potential. This observation, though attractive, does not appear to be supported by our data. In fact, our observation that M22 binds in a manner similar to or better than M47 to CBP or p300 and yet only the M47 mutant represses the c-Myb promoter does not support this hypothesis. The concept that Tax repression is independent of its interaction with CBP or p300 is further supported by the ®nding that Tax V89A is defective in both CBP and p300 binding and yet still transrepresses the c-Myb promoter. In contrast, M22 binds to CBP and p300 but does not repress the c-Myb promoter. Thus, our results indicate that Tax-mediated repression of the c-Myb promoter is independent of its binding to CBP or p300 and is mediated by alternative mechanism(s).
Tax is known to up-regulate expression of many cellular genes by stimulating their transcription through CREB/ATF, NF-kB or SRE pathways. Therefore, one possibility for Tax repression of the cMyb promoter is to up-regulate the expression of a repressor of c-Myb transcriptional activity. Alternatively, Tax could repress the expression of an activator of c-Myb transcriptional activity. We are currently attempting to identify factors that may be involved in Tax-mediated transrepression of the c-Myb promoter.
The c-Myb protein is phosphorylated on serine and threonine at multiple sites in vivo (Luscher et al., 1990; Aziz et al., 1995; Bading et al., 1989) and phosphorylation has been implicated in the control of c-Myb transcriptional activity (Oelgeschlager et al., 1995; Miglarese et al., 1996) . Whether Tax alters phosphorylation of c-Myb and that this could contribute to the transrepression phenotype described here is under investigation.
Tax transrepression on the endogenous c-Myb promoter was observed in HTLV-I transformed cells. Several studies have demonstrated that c-Myb is essential in cell cycle G1/S progression of normal lymphoid and leukemia cells (Thompson et al., 1986; Venturelli et al., 1990; . In HTLV-I-infected cells, Tax inhibits cellular proteins that regulate cell cycle checkpoints, such as p16
, p53, and MAD-1 (Suzuki et al., 1996; Cereseto et al., 1996; Akagi et al., 1997; PiseMasison et al., 1998; Mulloy et al., 1998; Jin et al., 1998) . Furthermore, Tax induces cyclin D2 upregulation and the consequent hyper-phosphorylation of the retinoblastoma (Rb) protein and constitutive cyclin E-CDK2 activity (Neuveut et al., 1998; Cereseto et al., 1999) . Thus, it is tempting to speculate that, in HTLV-I-infected T-cells, Tax may override the physiological role of c-Myb in cell cycle progression. Another important function of the c-Myb protein, upregulation of Bcl2 expression and protection against apoptosis, may be dispensable since HTLV-I infection has been shown to result in an increased expression of anti-apoptotic Bcl2 and Bcl-XL proteins (Nicot et al., 1997; Nicot et al., in press ). Recently, c-Myb was shown to repress up to 60% of the transcriptional activity from the Ras promoter (Ganter and Lipsick, 1997) . Previous studies have demonstrated that Ras cooperates with Tax and increases transforming activity in vitro as well as tumorigenic potential of Tax in vivo (Pozzatti et al., 1990; Matsumoto et al., 1994) . Therefore, Tax repression of c-Myb expression might have pleiotropic eects in HTLV-I infected cells and contributes to leukemogenesis.
Since high levels of c-Myb are present in many cancers, including leukemias, colon cancer, neuroblastoma, breast cancer, and lung carcinoma (Alitalo et al. 1984; Grin and Baylin, 1985; Thiele et al., 1988; Guerin et al., 1990) , understanding the mechanisms underlying Tax-mediated c-Myb repression may reveal new targets for the treatment of these diseases.
Materials and methods
Cell lines
Jurkat, JPX9 and HTLV-I infected T-cell lines (MT-2, MT-4, C8166, C91/PL, C10MJ, MJ, 1185, 1186) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum in the presence of 100 units/ml penicillin; 100 mg/ml streptomycin, 2 mM glutamine and 50 U/ ml IL2 were added when required. The 293T cell line was maintained in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum in the presence of 100 units/ml penicillin and 100 mg/ml streptomycin, 2 mM glutamine.
Transient transfection and reporter assay
Transfections were performed using early passage of Jurkat T-cells (less than 30 passages). Twenty-four hours before transfection the cells were diluted with 10 volumes of fresh media. The following day, 5610 6 cells were plated in a 60 mm dish in complete media and transfections were carried out using the Superfect reagent (Quiagen) according to the manufacturer's instructions. The total amount of transfected DNA (5 mg) was normalized by adding pCDNA, and 100 ng of CMV-Renilla (Promega) were co-transfected to control for transfection eciency. Thirty-six hours after transfection, the cells were harvested, washed in phosphate buer saline (PBS), solubilized in 100 ml of reporter lysis buer (Dual Luciferase Reporter Assay, Promega Corporation) and assayed for luciferase activity using a Bertholdt luminometer. Results were adjusted for transfection eciency using the CMV-RL. Results including standard deviations are representative of three independent transfection experiments.
Plasmid constructs
Expression and reporter constructs used in this study have been previously reported: c-Myb promoter-luciferase constructs (McCann et al., 1995; Guerra et al., 1995) , CMV-cMyb expression vector , RSV-T7-CBP (Chrivia et al., 1997) , CMV-T7-p300 (Eckner et al., 1994) , pCMV4 WT Tax, M47 and M22 (Smith and Greene, 1990) , and Tax V89A and pET11-TaxH6 wild type Tax and Tax mutants M22, M47, V89A (Harrod et al., 1998) .
In vitro translation
Supercoiled plasmid DNA was isolated using Quiagen maxiprep extraction kit. 1.5 mg for Tax and 3 mg for CBP or p300 were added to a T7 polymerase-rabbit reticulocyte-based in vitro transcription-translation system (Quick TNT; Promega Corporation) in a ®nal volume of 50 ml. Proteins were labeled with 35 S-methionine (Dupont/NEN). Each in vitro translation reaction was carried out for 2 h at 308C. 2 ml from each reaction were resolved by SDS ± PAGE 4 ± 20% Tris-Glycine (Novex), immersed in autoradiography enhance solution Down-regulation of c-Myb expression by HTLV-I tax C Nicot et al (Dupont/NEN), dried for 2 h at 808C and exposed to an Xray ®lm at 7708C.
Protein binding and immunoprecipitation
In vitro translated radiolabeled Tax proteins were quanti®ed by PhosphorImager and comparable amounts of Tax and Tax mutant proteins were used in each binding reaction. Luciferase radiolabeled protein was synthesized from a vector supplied in the TNT Kit and was used as negative control. Binding was carried out overnight with gentle agitation at 48C in the following buer: Tris 50 mM, NaCl 50 mM, DTT 1 mM, EDTA 1 mM, glycerol 7.5%, Triton 0.1%, BSA 2.5 mg/ml, sodium orthovanadate 1 mM, Aprotinin, and Leupeptin. Antibodies were added for 2 h at 48C followed by protein A/G agarose beads (Life Technologies) for 2 h at 48C. Immuno-complexes were washed twice with three volumes of the binding buer, collected by centrifugation, boiled 5 min in 16 loading buer and resolved on 4 ± 20% gradient gels (Novex). Speci®city of the antibody to CBP and p300 were con®rmed by the absence of Tax protein in the immunoprecipitate when Tax protein was incubated in the absence of radiolabeled CBP or p300 proteins.
Northern blot
Total cellular RNA was extracted using Trizol reagent (Life Sciences) following manufacturer's instructions. Aliquots of 5 mg of total RNA were separated on agarose-formaldehyde gel, transferred onto nylon membrane (SCH&SCH, Keene, NH, USA), and hybridized following standard procedures at 428C in presence of a 32 P-radiolabeled cDNA probes for cMyb, Tax or GAPDH control. The membranes were washed twice in 26SSC, 0.5% SDS, at room temperature and twice in 0.16SSC, 0.5% SDS, for 30 min at 568C and exposed to an X-ray ®lm at 7708C.
Western blot and antibodies
Total protein extracts (50 mg) were resolved on 10% TrisGlycine gels (Novex) and transferred onto PVDF membranes (Millipore). Non-speci®c sites were blocked for 30 min in PBS-milk 5% at room temperature (RT), incubated overnight at 48C with primary antibodies and for 2 h with a secondary antibody-linked horseradish peroxydase (HRP). Immunoblots were washed and detection was performed using the chemiluminescence ultra signal (Pierce). c-Myb mouse monoclonal (clone 1-1) and CBP (C-20) antibodies were purchased from Upstate Biotechnology, p300 (C-20) from Santa Cruz Biothechnology, and b-tubulin monoclonal antibody (Ab-1) from Oncogene. Tax mouse monoclonal antibody was obtained through the NIH reagent program.
